

Rodrigo J Carbajo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2544212/publications.pdf>

Version: 2024-02-01

15
papers

471
citations

933447

10
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

794
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 340-349.	5.4	28
2	Relating Conformational Equilibria to Conformer-Specific Lipophilicities: New Opportunities in Drug Discovery. <i>Angewandte Chemie - International Edition</i> , 2022, 61, e202114862.	13.8	10
3	Relating Conformational Equilibria to Conformer-Specific Lipophilicities: New Opportunities in Drug Discovery. <i>Angewandte Chemie</i> , 2022, 134, .	2.0	0
4	Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS ^{G12C} . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6940-6952.	6.4	29
5	Diversity-Orientated Synthesis of Macrocyclic Heterocycles Using Double SNAr Approach.. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 6274-6290.	2.8	0
6	Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-mer) Peptides. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17287-17303.	6.4	6
7	Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degradator and Antagonist. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14530-14559.	6.4	59
8	Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS ^{G12C} . <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4468-4483.	6.4	55
9	Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments. <i>Journal of the American Chemical Society</i> , 2020, 142, 4904-4915.	13.7	32
10	Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9418-9437.	6.4	25
11	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88 ^{L265P} Mutant Diffuse Large B Cell Lymphoma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9918-9930.	6.4	13
12	Building Bridges in a Series of Estrogen Receptor Degradators: An Application of Metathesis in Medicinal Chemistry. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1492-1497.	2.8	9
13	Observing an Antisense Drug Complex in Intact Human Cells by in-Cell NMR Spectroscopy. <i>ChemBioChem</i> , 2019, 20, 2474-2478.	2.6	38
14	Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. <i>ACS Chemical Biology</i> , 2018, 13, 3131-3141.	3.4	110
15	Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4386-4402.	6.4	57